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Abstract
Background: Prevention of diarrhea has presented indomitable challenges. A preventive strategy that has received
significant interest is zinc supplementation. Existing literature including quantitative meta-analyses and systematic
reviews tend to show that zinc supplementation is beneficial however evidence to the contrary is augmenting. We
therefore conducted an updated and comprehensive meta-analytical synthesis of the existing literature on the
effect of zinc supplementation in prevention of diarrhea.
Methods: EMBASE
®, MEDLINE
® and CINAHL
® databases were searched for published reviews and meta-analyses
on the use of zinc supplementation for the prevention childhood diarrhea. Additional RCTs published following the
meta-analyses were also sought. Effect of zinc supplementation on the following five outcomes was studied:
incidence of diarrhea, prevalence of diarrhea, incidence of persistent diarrhea, incidence of dysentery and incidence
of mortality. The published RCTs were combined using random-effects meta-analyses, subgroup meta-analyses,
meta-regression, cumulative meta-analyses and restricted meta-analyses to quantify and characterize the role of
zinc supplementation with the afore stated outcomes.
Results: We found that zinc supplementation has a modest beneficial association (9% reduction) with incidence of
diarrhea, a stronger beneficial association (19% reduction) with prevalence of diarrhea and occurrence of multiple
diarrheal episodes (28% reduction) but there was significant unexplained heterogeneity across the studies for these
associations. Age, continent of study origin, zinc salt and risk of bias contributed significantly to between studies
heterogeneity. Zinc supplementation did not show statistically significant benefit in reducing the incidence of
persistent diarrhea, dysentery or mortality. In most instances, the 95% prediction intervals for summary relative risk
estimates straddled unity.
Conclusions: Demonstrable benefit of preventive zinc supplementation was observed against two of the five
diarrhea-related outcomes but the prediction intervals straddled unity. Thus the evidence for a preventive benefit
of zinc against diarrhea is inconclusive. Continued efforts are needed to better understand the sources of
heterogeneity. The outcomes of zinc supplementation may be improved by identifying subgroups that need zinc
supplementation.
Background
Preventing childhood diarrheas is difficult but impor-
tant, especially in developing countries. An intensely
studied and evaluated effort in this direction focuses on
zinc supplementation since this micronutrient is
believed to play a critical role in the pathogenesis of
childhood diarrheas. Zinc is one of several important
trace elements that have far-reaching effects on multiple
organs and systems and serves over 300 biological func-
tions [1]. Therefore it is argued that chronic zinc defi-
ciency may increase diarrhea susceptibility.
On the basis of the substantial body of biological evi-
dence, it can be envisaged that zinc supplementation to
children with zinc deficiency may help arrest or at least
lessen diarrheal incidence and prevalence. For example,
owing to the differential distribution of the prevalence
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WHO/UNICEF recommends therapeutic zinc supple-
mentation for diarrhea only in developing countries but
not in developed countries [2,3]. While guidelines for
zinc supplementation during an episode of diarrhea are
clearer, there is currently no unified view about the
need to provide zinc supplementation as a preventive
measure to curb the incidence and prevalence of diar-
rhea. Three published meta-analyses have thus far evalu-
ated the use of zinc supplementation in the scenario of
diarrhea prevention[4-6]. The first meta-analysis by
Bhutta et al[5] included seven studies and showed an
overall 18% reduction in incidence of diarrhea attributa-
ble to zinc supplementation. The second meta-analysis
included 15 studies[4], reported a slightly lesser but still
significant benefit of a 14% reduction in incidence of
diarrhea. The most recent meta-analysis[6] included 24
studies with 33 distinct comparisons. It showed a 20%
reduction in incidence of diarrhea. Interestingly, the
meta-analyses by Aggarwal et al[4] reported a statisti-
cally significant heterogeneity across the published
studies.
In spite of these elegant reports, there exist several
gaps in the current understanding of the potential bene-
fit of zinc supplementation as a prophylactic measure.
First, the observed heterogeneity across published stu-
dies somewhat questions the reliability of the summary
effect measures that have been heretofore ascribed to
zinc supplementation. Second, several additional trials
[7-12] have been published since the last meta-analysis
and a formal synthesis inclusive of the newer evidence is
currently lacking. Third, the published meta-analyses
have reported the influence of zinc supplementation on
overlapping as well as different diarrheal outcomes but a
single compiled report on these different outcomes is
not available. Finally, the temporal relevance of zinc
supplementation as a public health measure against
childhood diarrhea is not known. We therefore con-
ducted the present study with the following three aims:
i) to update the meta-analysis of preventive use of zinc
in children for most commonly reported diarrheal out-
comes; ii) to understand the sources of heterogeneity, if
any; and iii) to understand if the evidenced-based benefit
attributable to zinc has changed over time.
Methods
Data Extraction
We attempted to include all the recent published rando-
mized controlled trials (RCT) that have been published
after the three meta-analyses[4-6] were published. We
also aimed to include additional past RCTs which may
not been included in the previous meta-analyses. The
search strategy and the search protocol are detailed in
Figure 1A. To identify these studies we again searched
the EMBASE
®,C I N A H L
® and MEDLINE
® databases
for recently published trials on zinc supplementation.
We searched using the following keywords: “zinc” and
“diarrhea” and “supplement” limited to “humans” and
“trials”. We included studies that gave zinc supplemen-
tation for at least two weeks, had a length of follow-up
of at least four weeks and in which the relative risk esti-
mates were either reported or computable. All trials that
provided zinc supplements with or without other nutri-
ents versus the same preparation minus zinc were
included. Trials that began as therapeutic trials to treat
acute or persistent diarrhea and followed the children
for prevalence or incidence of subsequent diarrhea were
also included, provided they fulfilled the inclusion cri-
teria stated above. As shown in Figure 1A, we excluded
trials that did not conform to a randomized controlled
trial design; reported outcomes unrelated to diarrhea;
had prohibitive number of co-interventions or co-infec-
tions or were not directly related with the topic of this
review. Our exclusion criteria resulted in the exclusion
of four trials that were included in previous meta-analy-
sis for following reasons: human immune-deficiency co-
infection [13], relative risk not computable [14], out-
come unrelated to diarrhea [15] and several co-interven-
tions [16].
Our search strategy identified a total of 37 trials
[7-12,17-47], the details of which are listed in Table 1.
After locating the studies, at least three investigators
independently evaluated each trial and inputs from
these sources were collated into the final data set. All
the authors independently reviewed the studies; any dis-
crepancies in the study evaluations were discussed and
resolved during one-to-one meetings. The report of this
review is provided in line with the PRISMA
® guidelines
(http://www.prisma-statement.org/index.htm) - the
checklist and flowchart are provided separately (see
Additional Files 1 and 2).
Analytical approach
We first attempted to classify the studies based on the
outcomes they reported (Figure 1, right panel). We
focused on five important and commonly reported out-
comes: incidence of diarrhea, prevalence of diarrhea,
incidence of persistent diarrhea, incidence of dysentery
and incidence of mortality. For each outcome, we stu-
died the reported effect sizes and the heterogeneity
across studies. For these meta-analyses, we used the ran-
dom effects model of DerSimonian and Laird [48].
For quantifying heterogeneity, we used two statistics:
the I
2 statistic and the τ
2 statistic that represents the
among-study variance. We also constructed 95% confi-
dence intervals for the τ
2 statistic using non-parametric
bootstrapping procedure [49] based on 5000 replicates.
The two heterogeneity quantifying statistics have
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4.  Studies remaining aŌer exclusion 20 
Number of studies                      31    15     11      7     12
Number of comparisons           38    16     12     8      14
 B.  Details of included studies  A.  Protocol for trial recruitment 
Figure 1 Studies included in this review. (A) Flowchart showing the search strategies and the exclusion criteria used to locate the relevant
studies in this review. (B) This panel lists the studies included in this synthesis and the outcomes (O1-O5) reported by each study. The
outcomes are color-coded and the colors are consistently used in the rest of the paper. A colored square in the grid indicates that the specified
outcome was reported by a trial while a blank square in the grid indicates that the outcome was not reported. The outcomes are as follows: O1,
incidence of diarrhea; O2, prevalence of diarrhea; O3, incidence of persistent diarrhea; O4, incidence of dysentery; O5, mortality. Total number of
studies and comparisons (when more than one zinc regimen was compared to the same reference group) are indicated at the bottom for each
outcome.
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Page 3 of 17Table 1 Baseline characteristics of the studies included in the systemic review
# Study Country Age
(m)
Sample
Size†
Zinc Supplementation Plasma
Zinc
(μg/dl)
Zn No
Zn
Dose
(mg)
Frequency/
wk
Duration
(wk)
Salt Zn No
Zn
1 Bates et al 1993 The Gambia 7-28 55 54 70 2 60 * - -
2 Ninh et al 1996 Vietnam 4-36 73 73 10 1 22 Sulphate - -
3 Sazawal et al 1996 India 6-35 286 293 10 7 26 Gluconate 64.7 65.0
4 Rosado et al 1997 Mexico 18-36 54 55 20 7 54 Methionate - -
5 Ruel et al 1997 Guatemala 6-9 45 44 10 7 28 Sulphate 97.4 95.8
6 Sazawal et al 1997 India 6-35 298 311 10 7 26 Gluconate - -
7 Gardner et al 1998 Jamaica 6-24 31 30 5 7 12 Sulphate 64.6 65.0
8 Lira et al 1998 Brazil 0-6 139 66 5 7 8 Sulphate - -
9 Umeta et al 2000 Ethiopia 6-12 100 100 10 7 26 Sulphate 78.0 70.3
10 Shankar et al 2000 Papua New Guinea 6-60 136 138 10 7 46 Gluconate 70.4 70.2
11 Muller et al 2001 Burkina Faso 6-31 356 353 12.5 7 26 Sulphate - -
12 Sazawal et al 2001 India 0 581 573 5 7 35 Sulphate - -
13 Rahman et al 2001 Bangladesh 12-35 325 161 20 7 2 - - -
14 Osendarp et al 2002 Bangladesh 1 152 149 5 7 24 Acetate 66.9 75.9
15 Bhandari et al 2002 India 6-30 1241 1241 10 7 16 Gluconate - -
16 Baqui et al 2002 Bangladesh 3-59 3974 4096 20 7 2 Acetate - -
17 Baqui et al 2003 Bangladesh 6 323 157 20 1 26 Acetate - -
18 Gupta et al 2003 India 6-41 186 94 10 7 16 Sulphate - -
19 Sur et al 2003 India 0-12 50 50 5 7 52 Sulphate - -
20 Lind et al 2004 Indonesia 6-12 340 170 10 7 26 Sulphate - -
21 Penny et al 2004 Peru 6-36 276 136 20 7 26 Gluconate - -
22 Alarcon et al 2004 Peru 6-35 111 224 0.7 6 18 Sulphate - -
23 Brooks et al 2005 Bangladesh 2-12 809 812 35 7 52 Acetate - -
24 Heinig et al 2006 USA 4-10 41 44 5 7 28 Sulphate - -
25 Sazawal et al 2006 Tanzania 1-35 8120 8006 10 7 56 - - -
26 Long et al 2006 Mexico 6-15 389 198 20 7 Methionate 71.0 76.0
27 Richard et al 2006 Peru 0.5-15 428 215 20 7 28 Sulphate - -
28 Tielsch et al 2006 Nepal 1-36 7297 14241 10 7 68 Sulphate - -
29 Tielsch et al 2007 Nepal 1-35 20968 20308 10 7 Sulphate - -
30 Gupta et al 2007 India 6-48 854 858 25 2 26 - - -
31 Sazawal et al 2007 Tanzania 1-36 21274 21272 10 7 68 - 78.0 79.0
32 Bhandari et al 2007 India 1-23 47110 47249 10 7 52 Sulphate 64.0 64.2
33 Luabeya et al 2007 South Africa 4-6 202 105 10 7 72 Gluconate 77.2 78.6
34 Brown et al 2007 Peru 6-8 203 99 3 7 26 Sulphate 77.1 78.6
35 Fischer Walker et al
2007
India, Pakistan,
Ethiopia
1-5 554 556 10 7 2 Sulphate - -
36 Chhagan et al 2009 South Africa 6-24 202 104 10 7 72 Sulphate - -
37 Taneja et al 2009 India 0 1026 1026 5 7 52 Sulphate 63.4 64.7
†Zn, zinc supplemented group; No Zn, zinc withheld group, details of the actual comparisons are provided in Supplementary Table (see Additional File 4)
* Mentioned as acetate/gluconate; -, not mentioned
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Page 4 of 17distinct merits in quantifying heterogeneity. The I
2 sta-
tistic can be compared across meta-analyses [50] and is
related to the related τ
2 s t a t i s t i cs u c ht h a ti tr e p r e s e n t s
the estimated proportion of the total or marginal var-
iance of a single study that is due to the among-study
variance[51]. Also, if a trial only reported the Cochrane
Q test result for heterogeneity then the I
2 statistic can
be estimated from it using the formula I
2 =( Q - d f ) / Q
with the minimum bound set to zero. On the other
hand, there are two advantages of using the τ
2 statistic:
first it can be used to estimate the 95% prediction inter-
vals for the global distribution of the estimated sum-
mary effect measure. Second, it can be used to estimate
the proportion of populations that are likely to show a
relative risk exceeding unity[52,53]. This parameter is
referred to here as the opposite affects proportion
[denoted in the rest of the paper by Pr(OE)]. The theo-
retical details underlying these two uses of the τ
2 statis-
tic are described in details in a supplementary note (see
Additional File 3).
Publication bias was examined using funnel plot [54]
and the regression intercept method described by Egger
at al[55]. We also used Duval and Tweedie’st r i ma n d
fill approach to examine the publication bias[56]. To
examine if the existing evidence points towards a chan-
ging benefit of zinc supplementation, we conducted
cumulative meta-analyses in which each subsequently
published study was added to meta-analysis and the pro-
cedure of DerSimonian and Laird [48] method repeated
iteratively. We evaluated all the included studies to iden-
tify possible risks of bias using the risk of bias assess-
ment tool recommended by t the Cochrane
Collaboration for Systematic Reviews [57]. The tool uses
six questions (see legend to Figure six A) to which the
answers can be summarized as no risk of bias, definite
risk of bias or uncertain risk of bias. To quantify the
overall risk of bias in a study we coded these three cate-
gories of responses as 1, 1.5 and 2, respectively and then
summated the scores for all the six questions. Thus the
total risk score varied in the range from 6 to 12 with a
score of six indicating no risk of bias and a score of 12
indicating a highly biased study. We then assessed if this
risk of bias score partly explained the variability in RR
estimates across studies.
We investigated the potential contributors to the het-
erogeneity with a three pronged approach: First, for con-
tinuous variables (age, plasma zinc concentration and
dose of zinc) we conducted univariate meta-regression
analyses as recommended by Higgins et al [50] and
Thomson et al [58] and attempted to quantify the extent
of contribution of the predictors to the heterogeneity.
Second, we conducted sub-group meta-analyses analyses
for the following categorical variables: continent of ori-
gin, zinc salt, countries classified by income categories,
zinc only studies, studies not included in previous meta-
analyses and studies with age-range up to 12 months.
For classifying the trial country into income groups, we
used the country-specific estimates of the Gross
National Income provided by the World Bank using the
Atlas method. (http://data.worldbank.org/data-catalog)
Third, the age of study subjects posed a special chal-
lenge in our meta-analysis. Most of the studies reported
the age as a range rather than mean. For the meta-
regression analyses explained in the first approach, we
therefore used mid-point of the age range as an approxi-
mation for the average age in a study and used these
mid-points for meta-regression. However, we also con-
ducted a complementary analysis in which we con-
ducted a set of restricted meta-analyses for each month
of age. For example, if we wanted to estimate the benefit
of zinc supplementation at 15 months of age then we
included only those studies in which the age range
straddled 15 months. We ran these restricted meta-ana-
lyses for each month of age over the range of 0-48
months and examined if the relative risk for the inci-
dence of diarrhea was stable at all ages.
Another challenge to our analytical approach was the
fact that some of the trials used a cluster-randomization
procedure. It has been extensively described that the
weights from a random effects model need to be appro-
priately adjusted to accommodate and overcome the
potential influence of design effect on summary esti-
mates in a meta-analysis[59,60]. We therefore, also
adjusted the random-effects models for the design effect
(which was reported in relevant trials) from cluster-ran-
domized trials. The adjustment for design effect was
done by multiplying the inverse-variance weight for a
study by design effect. The design-effect for trials that
did not use cluster randomization was treated as one.
Statistical analyses were conducted using the Stata 10.2
(Stata Corp, College Station, TX) software package. For
meta-analyses we used the metan.ado program written
by Bradburn [61] whereas for the cumulative and
restricted meta-analyses we used the metan.ado program
iteratively through dedicated Stata scripts.
Results
We included 37 identified studies (220,805 subjects) for
reports on one or more of the following five outcomes:
incidence of diarrhea, prevalence of diarrhea, incidence
of persistent diarrhea, incidence of dysentery and inci-
dence of mortality(Figure 1B). The number of studies
included for meta-analysis were: 31 for incidence of
diarrhea [7-12,17-21,23,25-28,30,31,33-39,41,43-47], 15
for prevalence of diarrhea [12,23,24,29,31-36,38,39,
41,43,44], 11 for incidence of persistent diarrhea
[21,30,33-36,38-40,45,46], 7 for incidence of dysentery
[18,30,34,36,40,45,46] and 12 for incidence of mortality
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sented 38, 16, 12, 8 and 14 distinct comparisons, respec-
tively (Figure 1B). The details of the specified
comparison groups for individual trials and the sources
of these studies are given in the Supplementary Table 1
(see Additional file 4).
Association of zinc supplementation with diarrheal
incidence
The summary relative risk estimate for incidence of
diarrhea was contributed by a total of 69934 and 75028
children in zinc and comparison groups, respectively.
Since some studies used more than one groups com-
pared to the same reference group, the total numbers of
comparisons used in this meta-analysis were 38 as
shown in Figure 2A. Our results indicated that there
was a 9% [summary relative risk estimate size 0.91, 95%
CI 0.87-0.95] lower incidence of diarrhea among chil-
dren who received zinc supplementation (Figure 2A).
The strength of this association did not change even
after adjusting for the design effect from cluster-rando-
mized trials (Figure 2A) and thus for the reason of sim-
plicity we report the findings from a standard random
effects model. The estimated value of τ
2 was 0.0107
(95% confidence interval 0.0049 - 0.0217). Using this
value of the among-study variance indicated that the
95% prediction interval for the summary relative risk
estimate was 0.73-1.13 and the Pr(OE) was 18% indicat-
ing that at the level of populations it may be premature
to assume a clear benefit of zinc supplementation and
that approximately 18% populations are likely to show a
relative risk estimate exceeding unity.
We considered two potential sources for a potentially
biased summary RR estimate in our meta-analysis. First,
since zinc was supplemented during episodes of acute
diarrhea in two trials [12,18] we considered whether
inclusion of these trials could have influenced our meta-
analysis. Sensitivity analyses (see Additional file 5)
showed that exclusion of these two trials had negligible
impact on the results of meta-analysis. Second, the fun-
nel plot (Figure 2B) indicated that was no significant
publication bias (Egger’s test: bias = -0.8; p = 0.12; Fig-
u r e1 B ) .W ee v a l u a t e dt h ep u b lication bias using Duval
and Tweedie’s trim and fill approach also and found
that no trimming was required and the results therefore
corroborated those of the Egger’s test.
To determine if there has been a temporal change in
the observed benefit of zinc supplementation we con-
ducted two sets of analyses. We first conducted cumula-
tive meta-analyses for the summary relative risk estimate
for incidence of diarrhea by iteratively including all stu-
dies that predated a specific trial. Significant benefit of
zinc was observed onwards from the fifth study group.
(Figure 2C) A striking observation from this cumulative
meta-analysis was that there was trend for a monotoni-
cally decreasing benefit of zinc with the chronological
rank of the studies. We thus considered the possibility of
using calendar year of publication year as a predictor of
the relative risk using meta-regression but could not con-
duct those analyses as the distribution of this variable
was skewed towards more recent years (Shapiro-Wilk’sp
= 0.027). Alternatively, to keep the size of subgroups
balanced, we categorized the trials into four classes based
on the quartiles of the publication year. We observed
(Figure 2D) that a significant protective benefit of zinc
was observed in the first two quartiles of publication year
but not in the third and fourth ones further substantiat-
ing the likelihood that the accumulation of more recent
evidence points towards a diminished preventive benefit
ascribable to zinc supplementation. To affirm this point
further, we considered whether the trials included in our
review that were not available for previous meta-analyses
demonstrated a lack of beneficial association of zinc sup-
plementation with diarrheal incidence. We observed that
seven comparison groups from five new trials
[7,8,11,12,62] indeed provided no evidence in favor of
zinc supplementation [summary RR estimate 0.99, 95%
CI 0.93 - 1.05] while the meta-analysis of the remaining
31 comparisons yielded statistically significant beneficial
association with zinc supplementation [summary RR
0.90, 95% CI 0.85 - 0.95].
An alternative way to measure the potential influence
of zinc on diarrheal incidence is to consider the out-
come of multiple episodes as has been done for other
conditions[51,63]. We thus examined if zinc supplemen-
tation affords a protection against occurrence of multi-
ple episodes of diarrhea. Only four trials [12,26,33,64]
explicitly stated this outcome. The remaining trials did
not clearly state whether the incidence is reported for
only first episodes or for subsequent episodes as well.
Three trials [12,26,33] reported the outcome as occur-
rence of ≥2 episodes of diarrhea while the remaining
trial [64] categorized the outcome as 0 episodes, 1-3 epi-
sodes, 4-6 episodes and >6 episodes. All the four trials
suggested a strong protective association of zinc supple-
mentation with multiple episodes of diarrhea. Meta-ana-
lytic summary of three trials [12,26,33] indicated that
zinc supplementation afforded a 31% protection against
occurrence of ≥2 episodes [summary relative risk esti-
mate = 0.69, 95% CI 0.53 - 0.95, 95% prediction interval
0.44 - 1.09, Pr(OE) 1.9%] although there was heteroge-
neity in the results (I
2 68%, τ
2 0.0317, 95% CI for τ
2
0.0231 - 0.284).
Investigation of heterogeneity across studies on diarrheal
incidence
In both the overall and the cumulative meta-analyses
there was a statistically significant heterogeneity of
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Figure 2 Meta-analysis of the influence of preventive zinc supplementation on the incidence of diarrhea. (A) Forest plot showing the
point (squares proportional to study weight) and 95% confidence interval (error bars) estimates for each study. Colored background indicates
harm (pink) or benefit (blue) of zinc supplementation. Summary relative risk estimate is shown as a diamond both by the random effects model
("Overall”) and corrected for the design effect from cluster-randomized trial ("Corrected for clustering effect”). The 95% prediction interval (PI) is
shown as a standard normal curve. Suffixes a and b indicate comparisons within a single study against the same placebo as detailed in
Supplementary Table (see Additional File 4). RR, relative risk; weight, percentage weight; Pr(OE) opposite effects proportion. (B) Funnel plot for
the investigation of publication bias. (C) Cumulative meta-analyses of chronologically ordered studies. Results are shown as the point estimate of
the effect size (purple diamonds aligned to the left y-axis) and the I
2 statistic (blue squares aligned to the right y-axis). Results are shown from
study group five onwards for which significant effects were observed (D) Contribution of calendar year to zinc supplementation. Results are
represented as point estimates (diamonds) 95% CI (error bars) and 95% PI (standardized normal curves). Heterogeneity is shown as I
2. The
estimates for τ
2 were: study groups 1-9: 0.0232 (95% CI 0.0029-0.1407); study groups 10-19: 0.0143 (95% CI 0.0033-0.0712); study groups 20-28:
0.0055 (95% CI 0.0000-0.0313); and study groups 29-38: 0.0062 (95% CI 0.0000-0.0231).
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Page 7 of 17effects across the published studies (I
2 65.5%, τ
2 0.0107,
95% CI for τ
2 0.0049 - 0.0217). We therefore proceeded
to investigate if the reported trial characteristics can
partially explain this heterogeneity. Specifically, we
examined the contribution of the following variables to
heterogeneity: age, continent of origin, country economy
(as a surrogate for prevalence of zinc deficiency), zinc
salt, duration of zinc supplementation, dose of zinc sup-
plementation and co-interventions. As shown in Table
1, only 12 of the included studies reported the baseline
plasma zinc level and hence we could not the influence
of this variable on heterogeneity.
We examined the contribution of age to heterogeneity
in three ways. First, the restricted meta-analysis for each
month of age showed (Figure 3A) that the relative risk
of diarrhea was strongly inversely correlated with age.
We found that there was a strong positive correlation
(Pearson’s r = 0.82, p < 0.0001) between age and the
summary relative risk for incid e n c eo fd i a r r h e ai n d i c a t -
ing that the beneficial association of zinc supplementa-
tion, on an average, increased by 0.31% for each month
of age starting from a benefit of 7.4% (95% CI 5.7% -
9.2%) at age zero. Maximum benefit of zinc supplemen-
tation (26%) was observed above 36 months but this
association was contributed to by only 6 studies (Figure
3A). Second, using the alternative approach of meta-
regression we found that age explained 6.3% of the het-
erogeneity across studies and had a significant associa-
tion (p = 0.014) with the reported incidence of diarrhea
(Figure 3B). Third, we categorized the included studies
into two groups - those in which the age range was
entirely below 1 year and the remaining studies. Sub-
group meta-analysis using this dichotomization
indicated (Table 2) that statistically significant associa-
tion could not be found in studies recruiting all children
less than one year of age. Thus, three complementary
approaches implied that zinc supplementation may ben-
efit more by restricting it to higher ages. It should be
noted however, that the 95% prediction intervals were
non-significant at all ages.
I nt h es u b g r o u pa n a l y s e s ,w ef o u n dt h a tt h e1 9s t u d y
groups from Asia [11,12,18,19,21,23,25,26,28,33,34,
41,44-46] showed a significant reduction in diarrheal
incidence but with large heterogeneity among study
groups. In contrast, studies from Americas [17,27,
30,31,35,37-39], Africa [7-10,20,47] or Oceania [43]
could not demonstrate a significant benefit of zinc for
this outcome (Table 2). Corroborating these results, we
also found (Table 2) that trials from the countries in the
lower middle income group [11,12,25,26,28,39,43,44,
64,65] demonstrated the strongest benefit of zinc sup-
plementation while trials from countries in the upper
middle [7,8,17,30,31,35,37,38] or high income group [27]
did not demonstrate such a benefit. Surprisingly, we
found that studies from the low income group countries
[9,10,18-20,23,33,34,36,45-47] also failed to demonstrate
beneficial utility of zinc against diarrheal incidence.
With regard to zinc salt, majority of the studies used
either zinc sulphate (18 study groups, [9,11,12,17,25,
27,28,31,33,37,39,44-46]) or zinc gluconate (7 study
groups, [7,8,21,35,43,65]). We found that the trials using
zinc gluconate showed the most significant reduction in
diarrheal incidence with no heterogeneity while the
trials using zinc sulphate (and those which did not men-
tion the salt used) also showed a statistically significant
reduction in diarrheal incidence. The trials that used
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2.72
1.65
1.00
0.61
0.37
1.00
0.95
0.90
0.85
0.80
0.75
0.70
0                12               24               36               48
R
e
l
a
t
i
v
e
 
r
i
s
k
 
f
o
r
 
i
n
c
i
d
e
n
c
e
 
o
f
 
d
i
a
r
r
h
e
a
R
e
l
a
t
i
v
e
 
r
i
s
k
 
f
o
r
 
i
n
c
i
d
e
n
c
e
 
o
f
 
d
i
a
r
r
h
e
a
N
u
m
b
e
r
 
o
f
 
s
t
u
d
i
e
s
 
i
n
c
l
u
d
e
d
35
30
25
20
15
10
5
0
A B
Decrease in I2 = 6.3%
Age (m) Mean Age (m)
CI for slope =-0.1652 - -0.0183
RR = exp[-0.0918*age(yrs) + 0.0138]
Figure 3 Association of age of the study subjects with the benefit of zinc supplementation. (A) Results from restricted meta-analysis for
each month of age (x-axis). Restricted meta-analysis was conducted for each month of age by including only those studies in which the range
of age of the study subjects straddled the selected month of age. Left y-axis (green) shows the relative risk for incidence of diarrhea while the
right y-axis (grey) shows the number of studies included in meta-analysis (B) Meta-regression. In this analysis the mid-point of the age range for
each study was meta-regressed onto the relative risk of observed diarrheal incidence in that study. Each circle represents a trial - the diameter of
a circle is proportional to the standard error in that study. Dark green line is the predicted regression line. Meta-regression on this variable
indicated that accounting for age would reduce the I
2 statistic by 6.3%. Pslope indicates the significance value for the test of a two-tailed null
hypothesis that the slope of the regression line is zero.
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Page 8 of 17zinc acetate were homogenous but did not show a sig-
nificant reduction in relative risk of diarrhea. Lastly, we
found that the trials supplementing zinc for a duration
of 10-26 weeks [17,19,21,25,26,28,31,33-35,41,47]
showed a reduced likelihood of diarrhea but trials using
zinc supplementation for shorter [12,18,36] or longer
[7,8,10,11,20,23,27,30,37-39,43-46,62] duration than this
interval did not show a statistically meaningful benefit
for the outcome of diarrheal incidence.
One of the main challenges in our meta-analyses was
the consideration of co-interventions. Figure 4 shows
the network diagram for the various comparisons
observed in the included studies. Formal network meta-
analysis (mixed treatment comparisons) [66-70] could
not be done because the treatment regimens used in
various studies (Figure 4) cannot be considered fully dis-
crete [69,70]. We thus classified the studies into three
groups - those that compared zinc supplementation
versus placebo,[7,9-12,20,23,25-28,30,31,33,34,36,37,39,
43,44,47,64] those that compared the combination of
zinc with some co-intervention that was also given to
the reference group (referred to as zinc + x versus x in
Table 2) [17-19,35,41] and those that combined two
more co-interventions with zinc but gave only one co-
intervention to the reference group (referred to as zinc
+ x + y versus y in Table 2) [7,8,19,30,37,38,45,46].
Interestingly, we observed that (Table 2) the benefit of
zinc supplementation could be ascertained from the
zinc versus placebo studies as well as the zinc + x versus
x studies but in the remaining studies this association
was not seen.
Next, using meta-regression we found that the dose of
zinc (p = 0.321), the total amount of zinc received
through supplementation (p = 0.467) or duration of zinc
supplementation (p = 0.418) did not influence the
observed benefit of supplementation and did not
Table 2 Results of subgroup analysis for the outcome of diarrheal incidence
Characteristic N SRR 95% CI 95% PI I
2 (%) τ
2 95% CI for τ
2 Pr(OE) %
Age category
Age range < = 12 months 12 0.95 0.88-1.02 0.77-1.18 69.9 0.0099 0.0000 - 0.0345 30.3
Remaining studies 26 0.89 0.83-0.94 0.71-1.12 61.9 0.0114 0.0029 - 0.0284 13.8
Type of comparison*
Zinc versus placebo 25 0.88 0.82-0.95 0.67-1.16 72.2 0.0173 0.0069 - 0.0404 16.6
Zinc+x versus x 5 0.90 0.85-0.96 0.84-0.96 6.7 0.0003 0.0000 - 0.0256 <0.001
Zinc+x+y versus y 8 0.98 0.82-1.04 0.80-1.20 21.2 0.0014 0.0000 - 0.0269 29.5
Continent of origin
Africa 8 0.92 0.79-1.08 0.67-1.26 43.7 0.0185 0.0000 - 0.1702 27.0
Asia 19 0.91 0.86-0.96 0.74-1.12 72.2 0.0099 0.0038 - 0.0252 17.2
Americas 10 0.90 0.80-1.01 0.66-1.22 68.7 0.0192 0.0059 - 0.0756 22.4
Oceania 1 0.99 0.32-3.06 —— — — —
Country economy
Low income 14 0.94 0.87-1.01 0.76-1.16 63.4 0.0089 0.0006 - 0.0393 25.6
Lower middle income 12 0.85 0.78-0.94 0.65-1.11 75.5 0.0154 0.0051 - 0.0540 9.5
Upper middle income 11 0.94 0.87-1.02 0.78-1.13 43.0 0.0068 0.0000 - 0.0294 22.7
High income 1 2.24 0.74-6.78 —— — — —
Zinc salt
Acetate 5 0.96 0.89-1.04 0.83-1.11 54.3 0.0037 0.0000 - 0.0118 25.1
Gluconate 7 0.91 0.87-0.95 0.87-0.95 0.0 0.0000 0.0000 - 0.0026 —
Methionate 3 0.95 0.76-1.19 0.63-1.42 74.6 0.0267 0.0005 - 0.1466 37.8
Sulphate 18 0.84 0.85-0.93 0.60-1.18 75.2 0.0276 0.0100 - 0.0742 14.7
Not mentioned 5 0.88 0.78-1.00 0.69-1.13 60.0 0.0112 0.0000 - 0.1171 11.4
Duration of supplementation
2-10 weeks 3 0.92 0.82-1.03 0.75-1.13 70.6 0.0067 0.0049-0.0124 15.4
10-26 weeks 15 0.85 0.78-0.93 0.63-1.14 75.5 0.0190 0.0056-0.0566 11.9
27+ weeks 20 0.94 0.89-1.00 0.78-1.13 51.2 0.0072 0.0000-0.0207 23.3
N, number of study groups; SRR, summary relative risk estimate; CI, 95% confidence interval based on DerSimonian and Laird model estimates; PI, 95% prediction
interval [details in supplementary note (see Additional File 3)]; τ
2, among-study variance; CI, confidence interval; Pr(OE), opposite effects proportion
*, For details please see text.
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Page 9 of 17contribute significantly to the between-studies heteroge-
neity. This result from meta-regression also corrobo-
rated the results from subgroup analysis (Table 2) which
showed that extremes of the duration of zinc supple-
mentation were not associated with benefit of zinc sup-
plementation. Together, our findings show that age,
continent and zinc salt were the three important charac-
teristics that could partly explain the significant hetero-
geneity of the beneficial association of zinc
supplementation in diarrheal incidence.
Lastly, we conducted risk of bias analyses to investi-
gate if existing risks of bias in the included studies
could provide clues into the source of among-study het-
erogeneity. Of the six potential biases investigated for,
we observed that a compilation of “other biases”
explained 18% of the among-study heterogeneity (p =
0.0309) while the remaining five biases did not individu-
ally afflict the among-study heterogeneity in a significant
way. Details of these biases for each study are provided
in Supplementary Table 2 (see Additional file 3). To
consider whether these biases might influence the
among-study heterogeneity in a concerted fashion, we
meta-regressed the total risk of bias score on the log of
reported RRs. We observed that (Figure 5B) there was
trend for a more significant association of zinc supple-
mentation with diarrheal incidence in studies that
showed a higher risk of bias (p = 0.062). Interestingly,
we also observed that there was a statistically significant
correlation between mean age in the trial and the risk of
bias (Pearson’s r = 0.34, p = 0.038) and therefore when
these two variables were together entered into a multi-
variate meta-regression model, both lost the statistical
significance (data not shown). Together these analyses
demonstrated that studies with high age group and
(sometimes concomitant) higher risk of bias were likely
to report a larger benefit attributable to zinc
supplementation.
Association of zinc supplementation with other outcomes
We next evaluated the influence of zinc supplementa-
tion on the remaining four outcomes described in Fig-
ure 1. The summary relative risk estimate for prevalence
of diarrhea was contributed by 15 studies [12,23,24,29,
31-36,38,39,43,44,65] which enrolled 3501 and 3033
children respectively in zinc and comparison group
without zinc. There was a 19% (summary relative risk
estimate 0.81, 95% CI 0.75-0.88; Figure 6) lower preva-
lence of diarrhea among children who received zinc
supplementation. However, there was significant hetero-
geneity of this effect as indicated by an I
2 statistic of
89.5%. For the outcome of incidence of persistent diar-
rhea 11 studies [21,30,33-36,38-40,45,46] with 12 distinct
comparisons which enrolled 31106 and 36899 children in
the zinc-supplemented and comparison group, respec-
tively were included in our meta-analysis. Our results
showed a non-significant association with on the reduc-
tion of risk by 11% (summary relative risk estimate 0.89,
95% CI 0.73-1.09) - a finding that was homogeneous
across the included studies (I
2 25%, Figure 6). The sum-
mary relative risk estimate for reduction of incidence of
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Figure 4 Network diagram representing various comparisons
found in the studies on diarrheal incidence. Eight different
reference groups are color coded and so are the comparisons
emanating from these reference groups. Each line represents a
comparison and the color-coded number alongside the line is the
number of trials reporting the specified comparison.
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Page 10 of 17dysentery was estimated from 7 studies [18,30,34,
36,40,45,46] with 8 distinct comparisons of 33391 and
39446 children respectively in zinc and comparison
groups. There was a non significant reduction of 11%
(0.89, 95% CI 0.75-1.06, Figure 6) with an I
2 of 38% indi-
cating homogeneity across studies. Finally, the effect of
zinc on mortality was assessed from 12 studies [10,11,
18,22,23,29,32,42,43,45,46,62] showing 14 distinct com-
parisons enrolling 111790 and 118140 children in zinc
and comparison group. Although there was a 10% reduc-
tion in the risk of mortality (summary relative risk esti-
mate 0.90, 95% CI 0.78-1.04, Figure 6) it did not achieve
statistical significance and again the findings were homo-
geneous as indicated by an I
2 of 48% (Figure 4). For these
four outcomes, we did not conduct subgroup meta-ana-
lyses or meta-regression owing to the small number of
studies. For all these outcomes the 95% prediction inter-
vals included a value of unity. For the outcome of preva-
lence of diarrhea, exclusion of the Fisher Walker et al
trial [12] (due to zinc supplementation during acute diar-
rhea) did not influence the summary relative risk esti-
mate while exclusion of the Baqui et al [18] trial for the
same reason further reduced the likelihood of a beneficial
association of zinc supplementation with dysentery. The
details of these analyses are provided in supplementary
meta-analyses (see Additional file 5).
Discussion
We reviewed a total of 37 studies that reported the value
of zinc supplementation in children for five different
diarrhea-related outcomes. We first considered our find-
ings in the light of the three previous meta-analyses of
preventive trials [4-6] that had observed a 14-20% reduc-
tion in the incidence of diarrhea in zinc supplemented
children. Since significant heterogeneity among trials was
observed we compared the point estimates for effect
sizes, their 95% confidence intervals, the total number of
studies and children included in this study with those in
the previously published meta-analyses (Table 3). Our
estimate of the protective benefit of zinc supplementation
was consistently lower that that reported in all previous
meta-analyses. Further, the 95% prediction intervals of
the summary relative risk estimate for all the five out-
comes in this meta-analysis straddled unity. With respect
to the outcome of diarrheal incidence however, it should
be noted that this outcome essentially deals with all (not
just the first) episodes of diarrhea during follow-up and
that the three trials that explicitly studied the association
of zinc supplementation with multiple episodes of diar-
rhea did demonstrate a significant benefit for the preven-
tion of ≥2 episodes.
In this study, cumulative meta-analyses helped to
sequentially update the summary relative risk estimate
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Figure 6 Forest plots for the meta-analysis of the influence of preventive zinc supplementation on four diarrhea outcomes- prevalence
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Page 12 of 17size by incorporating results from each newly available
study and also assess its impact on the heterogeneity.
We observed a steady decline in the protective afforded
by zinc with a corresponding decline in the heterogene-
ity which however remained significant (I
2 = 65.5%) till
the inclusion of the last study. Our investigation into
the potential sources of the observed heterogeneity of
results raises several interesting and important possibili-
ties. First, since a distinct slope for the effect size is
visualized (Figure 2C), it indicates instability of the
pooled effect size[71,72]. This instability indicates that
more and more negative studies (that is, studies report-
ing no clear benefit of zinc supplementation) have accu-
mulated over the recent past (a finding affirmed by our
subgroup analyses) and thus the clear benefit of zinc
observed during early years appears to have shrunken or
elapsed from more recent studies.
Second, it may be possible that there is a substantial
variability in the microbiological spectrum of the causes
of acute diarrhea across the studies. We have recently
[73] reported that the therapeutic benefit of zinc is not
equal against all organisms such that the Klebsiella spp
were most responsive to zinc supplementation, Esheri-
chia coli were neutral while rotavirus diarrhea was asso-
ciated with worse outcomes in zinc supplemented
children. It is conceivable that a similar phenomenon
may be operative in the scenario of diarrhea prevention
as well. This notion is also indirectly supported by our
observations that a significant benefit of zinc is not uni-
versally observed across continents of study origin or
countries classified on the basis of economy both of
which may somewhat reflect the heterogeneity in the
microbiological spectrum of causative organisms.
Third, in our meta-regression analyses, age was signifi-
cantly associated with the magnitude of the beneficial
association of zinc supplementation and explained 6% of
the heterogeneity. The restricted meta-analyses showed
a steep decline in the protection below 12 months of
age (Figure 3A, B). The previous meta-analyses of 24
studies with 33 distinct comparisons also validated that
the benefit of zinc supplements on diarrhea incidence
was limited to studies of children with mean initial age
greater than 12 months [6]. Considered in the light of
the causal gamut of childhood diarrheas, it is likely that
t h em o r ec o m m o np a t h o g e n sa ta g eb e l o w1 2m o n t h s
(for example, rotavirus infections) may be refractory to
the benefit of zinc supplementation at least as observed
in the context of diarrhea treatment. This finding indi-
cates that zinc supplementation may benefit substan-
tially by triaging on the basis of age.
Combined with these findings we also found that the
studies that recruited higher age groups seemed also to
be a higher risk of biases. Consequently, there is a puta-
tive circular relationship among age, bias and observed
effect. Alternative interpretations are possible in such a
scenario and the true interpretation is currently
unknown. For example, on the one hand it can be
argued (as stated thus far) that zinc may be beneficial at
higher age in reducing the prevalence and incidence of
diarrhea. On the other hand, it can also be argued that
the observed benefit of zinc at higher ages may be influ-
enced by implicit study biases and that more carefully
Table 3 Comparison of the results our study with those published previously
Outcome Meta-analysis RCTs N Statistic Point Estimate 95% CI I
2 (%)
Incidence of diarrhea M1 7 1502 OR 0.82 0.72 - 0.93 —
M2 15 6272 RR 0.86 0.79 - 0.93 77.3
M3 24 16665 RR 0.80 0.71 - 0.90 —
This study 31 144962 RR 0.91 0.86 - 0.95 65.5
Prevalence of diarrhea M1 7 1502 OR 0.75 0.63 - 0.88 —
This study 15 6534 RR 0.81 0.75 - 0.88 89.5
Incidence of persistent diarrhea M1 6 1770 OR 0.67 0.42 - 1.06 —
M2 3 2585 RR 0.75 0.57 - 0.98 56.3
This study 11 68005 RR 0.89 0.73 - 1.09 25.4
Incidence of dysentery M1 3 884 OR 0.87 0.64 - 1.19 —
M2 4 4250 RR 0.85 0.75 - 0.95 30.3
This study 7 72837 RR 0.89 0.75 - 1.06 37.9
Mortality M4 4 86152 RR 0.91 0.82 - 1.02 —
M3 10 201616 RR 0.94 0.86 - 1.02 —
This study 12 229930 RR 0.90 0.78 - 1.04 48.1
—, not reported
M1, Bhutta et al 1999[5]; M2, Aggarwal et al 2007[4]; M3, Brown et al 2009[6]; M4, Tielsch et al 2007[45]
OR, odds ratio; RR, relative risk; RCT, randomized controlled trial; CI, confidence interval
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are likely to shed more light on the magnitude of a true
zinc benefit in diarrhea prevention.
Fourth, the sub-group analyses also showed that zinc
salts may have a differential bearing on diarrheal inci-
dence. Studies that used zinc gluconate showed homo-
geneity and significant reduction in diarrheal incidence
(I
2 0%, summary relative risk estimate 0.90, 95% CI 0.86
- 0.94). Those using zinc sulfate were heterogeneous but
showed a statistically significant reduction in diarrheal
incidence (I
2 84.3%, summary relative risk estimate 0.75,
95% CI 0.63 - 0.89). There were fewer studies that used
zinc acetate and showed no benefit of zinc but were
homogenous. Elsewhere, we reported that a sub-group
analyses of therapeutic effect of zinc in reduction of
diarrheal duration also showed that studies using zinc
gluconate had a significant homogeneous reduction in
diarrheal duration although increased the risk of vomit-
ing[74]. These findings beckon a reconsideration of the
policy formulations regarding the salt to be used for
large scale zinc supplementation program aimed at diar-
rhea prevention. Together, these findings from cumula-
tive and sub-group analyses provide clues into the
heterogeneity of results from various studies of zinc sup-
plementation for diarrhea prevention.
It is noteworthy that Asia has the largest population of
stunted children[75-77]. It is expected that those coun-
tries at high risk of zinc deficiency, i.e. prevalence stunt-
ing exceeding 20% and estimated prevalence of
inadequate zinc intake of more than 25%, would most
likely benefit from prophylactic and therapeutic zinc
supplementation[78]. In this context it is interesting that
our findings from the sub-group analyses that studies
only from Asia demonstrated a favorable association of
zinc supplementation albeit with significant heterogene-
ity. Despite the food insecurity and poverty in develop-
ing countries of both Asia and Africa, studies from
Africa did not show a significant beneficial association
of zinc in reducing the risk of diarrhea and were homo-
genous. Anthropometric indices, baseline plasma zinc
levels or use of co-interventions may have differed
between studies in these continents.
Our estimate of the influence of zinc on the preva-
lence of diarrhea was slightly lower than that reported
by Bhutta et al[5] over a decade ago (Table 1). However,
that outcome had the highest heterogeneity across stu-
dies and therefore, although appealing, the summary
relative risk estimate size should be (metaphorically)
taken with a pinch of salt. More homogeneous studies
are needed before a conclusive impact of zinc can be
deduced on prevalence of diarrhea. In contrast to the
benefit of zinc for incidence and prevalence of diarrhea,
we could not demonstrate a clear benefit of this inter-
vention in reducing the incidence of persistent diarrhea,
dysentery and mortality. Two previous meta-analyses
that reported the effect of zinc on persistent diarrhea
reached opposite conclusions (Table 3) - one [4] showed
a significant effect while the other did not [5]. In con-
trast, therapeutic zinc supplementation during acute
diarrhea has been reported to have a clear benefit in
reducing the incidence of persistent diarrhea by ~25%
and in reducing the proportion of children with persis-
tent diarrhea > 3 days by ~30%[74]. This advantage of
zinc supplementation however does not appear to be
extending to prevention of persistent diarrhea. Similar
inconsistency was also observed for the effect of zinc on
the incidence of dysentery (Table 1). These results imply
that prevention of persistent diarrhea and dysentery may
not serve as realistic goals for preventive zinc
supplementation.
Finally, Tielsch et al [45] conducted a meta-analysis of
the effects of zinc supplementation on young child mor-
tality using two reports from South Asia and two from
Sub-Saharan Africa. The pooled estimated relative risk
of mortality across all ages for zinc supplementation was
0.91 (95% CI 0.82-1.02). A post hoc analysis showed that
zinc had a protective effect against mortality only in
children over 12 months [OR 0.82, 95% confidence
interval (CI) 0.70 - 0.96]; and in infants there was no
effect (OR 1.04 95% CI 0.90 - 1.21). The mortality
diminishing effects of zinc supplementation were also
equivocal in the subsequent review which included 10
studies (Table 1)[6]. Our systematic review shows that
adequately powered trials failed to demonstrate a signifi-
cant mortality reducing association of zinc supplementa-
tion in children less than five years. Based on these data,
we surmise that currently it is too premature to defini-
tively conclude about the role of preventive zinc supple-
mentation on mortality. However, it should also be
borne that our meta-analysis as well as the two previous
meta-analyses [6,45] have attempted to study the effect
of zinc supplementation on all-cause mortality. It is pos-
s i b l et h a tz i n cs u p p l e m e n t a t i o nm a yh a v em o r ep r o -
nounced effect on diarrhea-related or pneumonia-
related mortality [4,64] which may have been masked
when considering all-cause mortality.
Our meta-analyses had several strengths. First, as
shown in Table 3 our meta-analyses studied all the five
outcomes which, to our knowledge, no other study has
done in the past. Second, our meta-analyses were based
on several additional studies that the previous reviews
did not include. Third, cumulative meta-analyses
included in our study provided additional insights into
the chronological change in the pattern of zinc benefit.
Finally we attempted to probe the observed heterogene-
ity and conducted meta-regression and sub-analyses to
explain it. Our study also has several limitations. First,
only a few studies reported information on most of the
Patel et al. BMC Infectious Diseases 2011, 11:122
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regression analyses could not be conducted to under-
stand the importance of the factors identified in a multi-
variate context. Second, only covariates reported in the
trials can be examined but conceivably other known and
unknown predictors of zinc benefit may also partly
explain the observed heterogeneity. Third, meta-regres-
sion and subgroup analyses, in themselves, cannot be
considered as diagnostic tools but just provide clues
into the possible sources of heterogeneity. Fourth, due
to lack of reported data we could not fully tease out the
potential influence of socio-economic and nutritional
determinants of the differential benefit of zinc supple-
mentation. Fifth, we consistently observed a high degree
of heterogeneity across studies (sometimes even within
subgroups). Such high degree of heterogeneity can be
seen as a reason enough to question the validity of the
summary effect measures which might reflect an over-
simplification of the truth. Together, our findings urge
that more focused investigation of the potential sources
of heterogeneity is needed to refine and improve the
benefits from zinc supplementation for prevention of
diarrhea.
Conclusions
We observed that zinc supplementation reduces inci-
dence of diarrhea by 9% with more pronounced asso-
ciation observed beyond 12 months of age. We
attempted to translate this benefit into a perceptible
public health measure. A limitation of relative risk as a
measure of association is that decision making also
needs information on the extent of baseline risk. From
a practical perspective, measures such as number
needed to treat (NNT), which rely on the absolute
rather than relative risk reduction, are more informa-
tive [79-82]. Using the results of our meta-analyses, we
therefore estimated the number needed to prevent
(NNP) diarrheal episodes. An NNP of unity indicates
that all eligible children be provided the preventive
intervention[83]. Using the mathematical relationship
among relative risk, baseline risk, absolute risk reduc-
tion and NNP, we determined that an NNP of unity
can be achieved if the prevalence of children with at
least one diarrheal episode in year is 13.74% (95% CI
9.40% - 26.60%). Thus zinc supplementation of eligible
children would be appropriate for this range of preva-
lence of diarrheal episodes. It should also be noted
that we observed a significant benefit of zinc supple-
mentation against multiple episodes of diarrhea. How-
ever our cumulative meta-analyses showed that the
strength of benefit of zinc supplementation appears to
be shrinking as more studies are getting published.
Also, almost all the 95% prediction intervals reported
in this meta-analyses seemed to straddle unity
suggesting that a reproducible clear benefit of zinc supple-
mentation cannot be confidently inferred from the existing
evidence. Therefore the strategy of prophylactic zinc sup-
plementation for diarrheal prevention needs to be fine-
tuned. We also observed that zinc supplementation had
no demonstrable benefit against incidence of persistent
diarrhea, dysentery and mortality in children however it
should also be noted that the summary relative risk esti-
mate was consistently less than unity for all outcomes.
There is a continued need to understand sources of het-
erogeneity between studies so that zinc supplementation
targets the population that is most likely to benefit.
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